Logo

But Who's Gonna Pay For It?

Jan 04, 2007

One of the biggest stumbling blocks facing pharmacogenomics is getting insurance companies to realize the value of genetic testing and agree to foot the bill. That challenge is at the heart of this article from the San Jose Mercury News.

The article quotes David Lawrence, former chief executive of Kaiser Foundation Health Plan and Hospitals, as saying, "This is really a sea change in medicine. ... The whole question of what gets paid for and who pays it is going to take a while to get sorted out."

 

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.